Evandro de Azambuja: Prevention of brain metastases in patients with HER2-positive breast cancer
Evandro de Azambuja, Director of Membership for the European Society for Medical Oncology (ESMO), shared a recent article on LinkedIn:
“Our expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer is out. Volmar Müller, Thomas Bachelot, Giuseppe Curigliano, Jens Gempt, Julia Furtner-Srajer, Barbara Jereczek-Fossa, Katarzyna Jerzak, Emilie Le Rhun, Gabriella Pravettoni, Cristina Saura Manich and Rupert Bartsch.”
Title: Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer
Authors: Volkmar Müllera, Thomas Bachelotb, Giuseppe Curiglianoc, Evandro de Azambujae, Julia Furtnerf, Jens Gemptg, Barbara Alicja Jereczek-Fossac, Katarzyna J. Jerzaki, Emilie Le Rhunj, Carlo Palmierik, Gabriella Pravettonid, Cristina Sauran and Rupert Bartsch
Evandro de Azambuja is the Director of Membership for the European Society for Medical Oncology (ESMO) for the 2023-2024 term and the President of the Belgian Society of Medical Oncology (BSMO) from 2023 to 2026. He leads the Medical Support Team at the Jules Bordet Institute, previously known as the BREAST Data Centre. He has an extensive background in clinical research, particularly in breast cancer and clinical trials.
More posts featuring Evandro de Azambuja.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023